AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00812825
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
Trial: NCT00812825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
Trial: NCT00812825
Drug: Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
Trial: NCT01940692
Drug: 1.5g intravenous Exacyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of 1.5g Exacyl preoperatively
Trial: NCT01940692
Drug: 3.0g intra-articular Exacyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g Intra-articular Exacyl administration postoperatively
Trial: NCT03078751
Drug: Adjuvant endocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
Trial: NCT03078751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth.
Trial: NCT03090893
Drug: ATryn continuous infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: replenish serum thrombin levels
Trial: NCT01889277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00984399
Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
Trial: NCT00513461
Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02893371
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to all dosages and delivery forms.
Trial: NCT02893371
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to all dosages and delivery forms.
Trial: NCT02893371
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to all dosages and delivery forms.
Trial: NCT03078907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching film coated tablets
Trial: NCT02812251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered.
Trial: NCT03030105
Drug: BPN14770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug
Trial: NCT03030105
Drug: BPN14770 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00016978
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00016978
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00016978
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01177228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion
Trial: NCT03390933
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
Trial: NCT01605435
Drug: Ghrelin Group 1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
Trial: NCT01605435
Drug: Ghrelin Group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
Trial: NCT00466622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 tablets x 2 daily. Orally from Weifa
Trial: NCT04705883
Drug: Prasterone (DHEA), Micronized
RxNorm normalized name: prasterone (DHEA), micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
Trial: NCT01101139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: single intravenous injection Saline 0.9%
Trial: NCT03027505
Drug: Ready to Use Therapeutic Food (RUTF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day
Trial: NCT01013532
Drug: placebo of aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same size and shape of active aspirin 100mg
Trial: NCT02242240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02522130
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral treatment
Trial: NCT03219255
Drug: RELVAR 100 ELLIPTA
RxNorm normalized name: ECLIPTA PROSTRATA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
Trial: NCT00747058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02682225
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
Trial: NCT02682225
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
Trial: NCT04510103
Drug: Moisturizer A, F#9155-005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
Trial: NCT00074178
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00074178
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01076088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets to sitagliptin or metformin for 24 weeks.
Trial: NCT00516750
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00516750
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02919579
Drug: Placebo (Intranasal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
Trial: NCT02919579
Drug: Placebo (Oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
Trial: NCT00389090
Drug: Temozolomide and O6-Benzylguanine
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: O6BG + Temozolomide
Trial: NCT04566926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive matching placebo.
Trial: NCT00506922
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
Trial: NCT00823004
Drug: recombinant FSH or hMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant FSH or hMG 300-450 IU/day
Trial: NCT03474042
Drug: GLPG2737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
Trial: NCT03474042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
Trial: NCT00352053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir DF Placebo administered orally, daily + OBR
Trial: NCT00393198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
Trial: NCT01271153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
Trial: NCT02683213
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20mg once daily for 6 months.
Trial: NCT02683213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo.
Trial: NCT02884219
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
Trial: NCT02884219
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
Trial: NCT03082196
Drug: Test varnish
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of test varnish to the teeth 4 times per year.
Trial: NCT03082196
Drug: Standard varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of test varnish to the teeth 4 times per year
Trial: NCT02137239
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04313790
Drug: Heparin Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)
Trial: NCT01194882
Drug: Insuplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:
Trial: NCT01093183
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04355052
Drug: Hydroxychloroquine in combination of Azithromycin
RxNorm normalized name: combinations of barbiturates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
Trial: NCT01258296
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mcg/hr transdermal patch
Trial: NCT02251197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03887871
Drug: Harnal-D Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harnal-D Tab. 1T single oral administration after meal
Trial: NCT04533529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet will be administered orally once daily.
Trial: NCT05014906
Drug: Minocycline 45 MG
RxNorm normalized name: minocycline 45 MG
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Trial: NCT02990364
Drug: EMLA Topical Product
RxNorm normalized name: EMLA Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
Trial: NCT03953209
Drug: Spironolactone 50Mg Tablet
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
Trial: NCT03953209
Drug: Spironolactone 100Mg Tablet
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
Trial: NCT03953209
Drug: Spironolactone 200Mg
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
Trial: NCT04093466
Drug: CX1003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
Trial: NCT02515097
Drug: IDP-122 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical lotion with no active ingredient
Trial: NCT04670289
Drug: TenoMiR (Medium Dose)
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mimic of miR29a
Trial: NCT03277586
Drug: Probio'Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
Trial: NCT03277586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically formulated and packaged inactive substance
Trial: NCT02103426
Drug: ASP0113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular injection
Trial: NCT02103426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular injection
Trial: NCT04670289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT02189122
Drug: NHP544C 162 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take NHP544C 162 mg once a day for five days.
Trial: NCT02189122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take matching placebo for five days.
Trial: NCT04026074
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight adapted drug application
Trial: NCT04026074
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight adapted drug application
Trial: NCT04026074
Drug: Placebo iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration of 0,9% NaCl
Trial: NCT02264353
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One piece of placebo before sleep
Trial: NCT03194815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the control, or sham, treatment
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg MEDI-546 as a single IV dose
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg MEDI-546 as a single IV dose
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg MEDI-546 as a single IV dose
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg/kg MEDI-546 as a single IV dose
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mg/kg MEDI-546 as a single IV dose
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Trial: NCT00930683
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.0 mg/kg MEDI-546 as a single IV dose
Trial: NCT00051103
Drug: Investigational Cancer Drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025545
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025545
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01134718
Drug: TMC435 (G007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one morning dose of 150 mg
Trial: NCT04340141
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04340141
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03547024
Drug: Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
Trial: NCT00263783
Drug: MEDI-522
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
Trial: NCT01266499
Drug: both medications
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
Trial: NCT01266499
Drug: will not receive PO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will not receive PO treatment - will receive plecebo treatment
Trial: NCT01266499
Drug: PO Garamycin 80mg x 4/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO Garamycin 80mg x 4/d
Trial: NCT03274206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLS-ILB-E710c-placebo
Trial: NCT02617667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ocular, eye drops
Trial: NCT00427245
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes